Home Tags Drug Development
Drug Development Related Content
Here Dr. Harneet Arora, freelance neurologist, and FDA regulations expert, shares her advice on how to submit an application with FDA approval.
Diabetes UK and JDRF have announced their continued commitment to revolutionising Type 1 diabetes treatment, by awarding £490,000 to fund the next generation of immunotherapy research.
The University of Manchester found that a drug used for erectile dysfunction can slow or even reverse the progression of heart failure of sheep.
A five-year license has been issued to two companies allowing the cultivation and processing of medical cannabis products.
King's College London researchers found that cannabidiol (CBD) could hold promise as a treatment for psychosis, according to reasonable benefits seen in a clinical trial.
While Africa has made progress in tackling tuberculosis (TB), it still has one of the highest TB rates in the world and remains a priority.
Oxford Cannabinoid Technologies is a biopharmaceutical company combining cannabinoid medicine with world class scientific research and drug development.
On the 4th February 2019, a scientific breakthrough for the future of Alzheimer's brain reserach has been published - read on to explore the developments.
UCL’s Translational Research Office (TRO) builds on an increasingly vibrant translational culture across the university community.
English patients living in poorer areas are likely to be prescribed more opioids for pain by their GPs, according to a study led by University of Manchester and University of Nottingham researchers.
Kristin Stephenson, Sr. VP, Chief Policy & Community Engagement Officer at the Muscular Dystrophy Association details the advances taking place in newborn screening for neuromuscular disease
Professor of Developmental Mechanics at the Department of Genetics, University of Cambridge, Alfonso Martinez Arias shares his expert view on Organoids, within the field of developmental biology.
Managing Director of The Cancer Drug Development Forum, Prof. H. Zwierzina reveals his opinions on the current and future challenges of personalised cancer therapy, including the need for biomarkers.
Christophe Dugave & Karen Hinsinger from CEA-Saclay highlight an exciting European research project for de-risking drug innovation, ISOTOPICS
Professor of Organic Chemistry at University of York and Chairman of the Royal Society of Chemistry’s Heterocyclic and Synthesis Group, Peter O’Brien explores the role of heterocycles in the pharmaceutical industry In 2017, the Royal Society of Chemistry’s Heterocyclic and Synthesis Group celebrated its 50th anniversary. It thus appears timely...
Prof Thomas Jaki from the Medical and Pharmaceutical Statistics Research Unit at Lancaster University explores a novel approach to Ph.D. training for those in the pharmaceutical industry
Bethany Torr, campaigns and advocacy officer at Leukaemia Care introduces ‘Leukaemia’ and its different forms and explains how people live with the disease Leukaemia’ is an umbrella term for cancers of the white blood cells – ‘leuk’ means white and ‘aemia’ refers to a condition of the blood. 26 people are...
Cecilia Van Cauwenberghe, Vandana Iyer and Bhargav Rajan from Frost & Sullivan examine of how nanotechnology helps spot early stage cancer
Prof. David Dexter, deputy director of research at Parkinson’s UK shares his thoughts on the symptoms of Parkinson’s and the chances of finding a cure
Publishing national chemotherapy data has helped NHS hospitals make changes that should improve treatment, as Emma Saxon reveals in this article
12Page 1 of 2